Company Shares of Halozyme Therapeutics (NASDAQ:HALO) Drops by -0.22%

Halozyme Therapeutics (NASDAQ:HALO) has risen sharply, recording gains of 4.11% in the past 4 weeks. However, the stock has corrected -0.22% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.46% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The company shares have dropped -61.13% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $25.25 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $9.10 and the 200 Day Moving Average price is recorded at $10.00.

The stock has recorded a 20-day Moving Average of 4.62% and the 50-Day Moving Average is 1.84%.


Halozyme Therapeutics (NASDAQ:HALO): The stock was completely flat for the day, closing at $9.11 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $9.09, the stock touched an intraday high of $9.28 and a low of $8.85. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $9.11. The total trading volume on Friday was 1,381,336.

In an insider trading activity, Stelzer Laurie, CFO of Halozyme Therapeutics Inc, had purchased 10,000 shares on August 20, 2015. The total value of the transaction was $172,400. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *